People with Hodgkin lymphoma who have had at least 2 previous treatments and cannot have a stem cell transplant can now benefit from a new treatment option.

Pembrolizumab will soon be available in the NHS in England.

Learn more: nice.org.uk/guidance/ta968…

#NICENews

Children and teenagers could benefit after a new targeted combination treatment for a rare, aggressive form of brain cancer was recommended today.

Find out more about how dabrafenib with trametinib works: nice.org.uk/News/Article/c…

#NICENews

Our new guideline on vitamin B12 deficiency aims to raise awareness of the condition and help improve diagnosis and treatment so people affected can access the care they need.

Find out more: nice.org.uk/guidance/ng239…

#NICENews

Updated final guidance means 1.4million more people at risk of severe COVID-19 will have access to Paxlovid within three months.

The antiviral medicine is given as 2 separate tablets to people within five days of getting symptoms.

Learn more: nice.org.uk/guidance/ta878

#NICENews

People with advanced or recurrent womb cancer can be offered a 30-minute infusion treatment to treat their condition.

Dostarlimab has been recommended for use in the Cancer Drugs Fund.

Learn more: nice.org.uk/News/Article/n…

#NICENews

We've published final guidance on identifying genetic risk of ovarian cancer, along with recommendations for testing criteria and risk management strategies.

It also features useful and useable implementation tools to help with risk assessment: nice.org.uk/guidance/ng241

#NICEnews

Children and young adults could benefit after a personalised immunotherapy to treat an aggressive form of blood cancer was recommended for routine use.

Tisagenlecleucel was previously available via the Cancer Drugs Fund.

Learn more: nice.org.uk/guidance/gid-t…

#NICENews

People with advanced kidney cancer could benefit after a new combination treatment was recommended in final guidance today.

Cabozantinib with nivolumab for untreated advanced renal cell carcinoma can be offered to people in England.

Learn more: nice.org.uk/guidance/ta964… #NICENews

A new treatment option can be offered for children and young people aged between 6 and 17 years with Bardet-Biedl syndrome.

Setmelanotide is recommended for treating obesity and hyperphagia (extreme hunger) in this rare genetic condition⬇️

nice.org.uk/guidance/indev…

#NICENews

Our updated twin and triplet guideline recommends a cervical length scan between 16 and 20 weeks.

Treatment with progesterone is recommended if a short cervix is identified as it may reduce risk of pre-term birth.

Learn more: nice.org.uk/guidance/ng137

#NICENews

Our director of medicines evaluation, Helen Knight has welcomed the final draft guidance for dabrafenib with trametinib, which demonstrates NICE is getting the best care to patients fast, while ensuring value for the taxpayer ⬇️
#NICENews

People whose ovarian, fallopian tube and peritoneal cancer has responded to first-line platinum-based chemotherapy are set to benefit from a new treatment option.

Twice daily pill olaparib is recommended in final draft guidance.

Learn more: nice.org.uk/guidance/indev…

#NICENews

Thousands of people with low back pain could be offered access to five digital technologies to help manage their condition.

The platforms offer a variety of support including access to a multi-disciplinary team via video or text.

Learn more: nice.org.uk/guidance/hte16
#NICENews

Adults with a rare cancer of the bone marrow will soon benefit from a new treatment option.

Momelotinib is recommended for treating disease-related splenomegaly or symptoms in adults with myelofibrosis.

Learn more: nice.org.uk/guidance/indev…

#NICENews

People with multiple myeloma whose cancer is not responding to treatment could be offered a new triple drug combination.

Selinexor is taken as a tablet and helps to stop myeloma cells from multiplying.

Learn more: nice.org.uk/guidance/gid-t…

#NICENews

Children and young people aged between 6-17 years with Bardet-Biedl syndrome will soon be able to start a new treatment option.

NICE has recommended setmelanotide in final draft guidance for treating obesity caused by this rare genetic condition nice.org.uk/guidance/gid-t…
#NICENews

Thousands of people with severe hair loss due to alopecia areata are set to benefit from a new treatment option.
One-a-day tablet ritlecitinib has been recommended to help treat the condition.
Learn more: nice.org.uk/guidance/ta958
#NICENews

Hundreds of people can benefit from the first targeted combination treatment for the life-threatening rare bone marrow condition AL amyloidosis.

Daratumumab in combination with three other drugs has been recommended.
Learn more: nice.org.uk/guidance/ta959/
#NICENews

📢We’ve updated our guideline for detecting diagnosing and managing meningitis.

It now includes:

🔹Expanded coverage to include adults
🔹Updated info and support for patients
🔹Latest advice on recognising signs and symptoms

Find out more: nice.org.uk/guidance/ng240
#NICENews

A once-daily tablet can be offered to adults with BRCA 1 or 2 mutated HER2-negative locally advanced or metastatic breast cancer after prior chemotherapy.

Talazoparib has been recommended for NHS use by our independent committee.

Learn more: nice.org.uk/guidance/ta952
#NICENews